Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business

Medicilon, a one-stop pharmaceutical preclinical research and development CRO, can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND approvals to initiate clinical trials.

In recent years, based on the "API + formulation" one-stop CMC service platform, Medicilon has expanded from process R&D to industrial commercial production and committed to expanding from preclinical CRO to CRDMO, further strengthening our ability to collaborate with industry partners in the development of new drugs.

Wenjie Li.webp

Effective March 4 , 2024, Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon’s services in the CRDMO field, leading the CMC team to improve our R&D CMC capabilities to provide clients with better services efficiently.

Dr. Wenjie Li, holds a Bachelor's degree from Peking University and Masters and Ph.D. degrees in Organic Chemistry from the University of Pittsburgh. He is selected as Shuangchuang talents in Jiangsu Province, Chengdu City's Real Economy and New Economy Talents, and a pioneer in the Zijinshan talent program in Nanjing.

With nearly three decades in pharmaceutical R&D management, Dr. Wenjie Li has deep expertise in drug development, including CMC services and CRO/CDMO management, accumulating rich experience and profound knowledge. He is familiar with all the various stages of new drug and generic drug process development, manufacturing transfer, process validation, commercial production, and application. He is able to accurately control every aspect of drug R&D processes. Additionally, Dr. Li has outstanding academic achievements, publishing over 20 papers in international journals and receiving nearly 20 invention patents, contributing valuable insights to the industry.

Before joining Medicilon, Dr. Wenjie Li was engaged in innovative drug and generic drug process R&D and CMC management at Merck Research Laboratories (USA), Boehringer Ingelheim Pharmaceuticals, Sichuan Kelun Pharmaceutical Research Institute (China), and TransThera Bioscience Co., receiving multiple corporate awards for his outstanding performance and contributions. He also held key positions at WuXi AppTec's US branch and Kingchem Dalian PharmaScience, acquiring extensive experience and leadership skills. His diverse pharmaceutical background and rich work experience have provided Dr. Li with excellent technical capabilities and profound industry insights.

Dr. Wenjie Li, Vice President of CMC Unit at Medicilon, stated: "I am honored to join Medicilon. I am deeply impressed by Medicilon's strategic vision and ambition, and I admire Medicilon's dedication to empowering new drug discovery and development over the past two decades.

I appreciate Medicilon's trust in me. With my years of experience in drug R&D management, I believe I can inject new vitality into Medicilon's development. I look forward to working together with my team to provide high-quality and efficient services in the CMC field for our clients, further contributing to global drug discovery and development in a more impactful way."

Dr. Chunlin Chen, founder & CEO of Medicilon, said: "We welcome Dr. Wenjie Li to the Medicilon family! Dr. Li brings rich global industry experience. He possesses deep local management practice and an international strategic vision. His addition will bring valuable and diverse experience and opportunities to Medicilon's exploration of CRDMO services, helping achieve Medicilon 's strategic goals."

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客